Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group

Abby R. Rosenberg, James R. Anderson, Elizabeth Lyden, David A. Rodeberg, Suzanne L. Wolden, Simon C. Kao, David M. Parham, Carola A.S. Arndt, Douglas S. Hawkins

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging [computerised tomographic (CT) or magnetic resonance imaging (MRI) scan] is controversial. We previously reported no relationship between early response and failure-free survival (FFS) on Intergroup Rhabdomyosarcoma Study (IRS)-IV. We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS. Methods A total of 338 patients enrolled in Children's Oncology Group (COG) study D9803 met the inclusion criteria for this analysis: (1) non-metastatic, initially unresected (Group III); (2) embryonal (ERMS) or alveolar (ARMS) histology; (3) documented protocol week 12 response to induction chemotherapy (excluding progressive disease) based on anatomic imaging (CT/MRI) and (4) documented protocol therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR), partial response (PR) or no response (NR). FFS was estimated using the Kaplan-Meier method and comparisons between patient subsets were made using the log-rank test. Results Overall objective response rate (CR + PR) at week 12 of therapy was 85% and was similar between ERMS and ARMS. FFS was similar among all patients with CR, PR or NR (p = 0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by response within either histology subset (p = 0.89 and p = 0.08, respectively). Conclusions These findings provide additional evidence that anatomic imaging to assess early response to therapy among patients with RMS does not predict outcome and has questionable use in tailoring subsequent therapy.

Original languageEnglish (US)
Pages (from-to)816-823
Number of pages8
JournalEuropean Journal of Cancer
Volume50
Issue number4
DOIs
StatePublished - Mar 2014

Fingerprint

Rhabdomyosarcoma
Survival
Histology
Magnetic Resonance Imaging
Therapeutics
Induction Chemotherapy
Clinical Trials

Keywords

  • Paediatric cancer
  • Rhabdomyosarcoma
  • Sarcoma
  • Survival outcomes

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma : A report from the Children's Oncology Group. / Rosenberg, Abby R.; Anderson, James R.; Lyden, Elizabeth; Rodeberg, David A.; Wolden, Suzanne L.; Kao, Simon C.; Parham, David M.; Arndt, Carola A.S.; Hawkins, Douglas S.

In: European Journal of Cancer, Vol. 50, No. 4, 03.2014, p. 816-823.

Research output: Contribution to journalArticle

Rosenberg, Abby R. ; Anderson, James R. ; Lyden, Elizabeth ; Rodeberg, David A. ; Wolden, Suzanne L. ; Kao, Simon C. ; Parham, David M. ; Arndt, Carola A.S. ; Hawkins, Douglas S. / Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma : A report from the Children's Oncology Group. In: European Journal of Cancer. 2014 ; Vol. 50, No. 4. pp. 816-823.
@article{6925dc0add234a6c914697008182c864,
title = "Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma: A report from the Children's Oncology Group",
abstract = "Background The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging [computerised tomographic (CT) or magnetic resonance imaging (MRI) scan] is controversial. We previously reported no relationship between early response and failure-free survival (FFS) on Intergroup Rhabdomyosarcoma Study (IRS)-IV. We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS. Methods A total of 338 patients enrolled in Children's Oncology Group (COG) study D9803 met the inclusion criteria for this analysis: (1) non-metastatic, initially unresected (Group III); (2) embryonal (ERMS) or alveolar (ARMS) histology; (3) documented protocol week 12 response to induction chemotherapy (excluding progressive disease) based on anatomic imaging (CT/MRI) and (4) documented protocol therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR), partial response (PR) or no response (NR). FFS was estimated using the Kaplan-Meier method and comparisons between patient subsets were made using the log-rank test. Results Overall objective response rate (CR + PR) at week 12 of therapy was 85{\%} and was similar between ERMS and ARMS. FFS was similar among all patients with CR, PR or NR (p = 0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by response within either histology subset (p = 0.89 and p = 0.08, respectively). Conclusions These findings provide additional evidence that anatomic imaging to assess early response to therapy among patients with RMS does not predict outcome and has questionable use in tailoring subsequent therapy.",
keywords = "Paediatric cancer, Rhabdomyosarcoma, Sarcoma, Survival outcomes",
author = "Rosenberg, {Abby R.} and Anderson, {James R.} and Elizabeth Lyden and Rodeberg, {David A.} and Wolden, {Suzanne L.} and Kao, {Simon C.} and Parham, {David M.} and Arndt, {Carola A.S.} and Hawkins, {Douglas S.}",
year = "2014",
month = "3",
doi = "10.1016/j.ejca.2013.11.031",
language = "English (US)",
volume = "50",
pages = "816--823",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "4",

}

TY - JOUR

T1 - Early response as assessed by anatomic imaging does not predict failure-free survival among patients with Group III rhabdomyosarcoma

T2 - A report from the Children's Oncology Group

AU - Rosenberg, Abby R.

AU - Anderson, James R.

AU - Lyden, Elizabeth

AU - Rodeberg, David A.

AU - Wolden, Suzanne L.

AU - Kao, Simon C.

AU - Parham, David M.

AU - Arndt, Carola A.S.

AU - Hawkins, Douglas S.

PY - 2014/3

Y1 - 2014/3

N2 - Background The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging [computerised tomographic (CT) or magnetic resonance imaging (MRI) scan] is controversial. We previously reported no relationship between early response and failure-free survival (FFS) on Intergroup Rhabdomyosarcoma Study (IRS)-IV. We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS. Methods A total of 338 patients enrolled in Children's Oncology Group (COG) study D9803 met the inclusion criteria for this analysis: (1) non-metastatic, initially unresected (Group III); (2) embryonal (ERMS) or alveolar (ARMS) histology; (3) documented protocol week 12 response to induction chemotherapy (excluding progressive disease) based on anatomic imaging (CT/MRI) and (4) documented protocol therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR), partial response (PR) or no response (NR). FFS was estimated using the Kaplan-Meier method and comparisons between patient subsets were made using the log-rank test. Results Overall objective response rate (CR + PR) at week 12 of therapy was 85% and was similar between ERMS and ARMS. FFS was similar among all patients with CR, PR or NR (p = 0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by response within either histology subset (p = 0.89 and p = 0.08, respectively). Conclusions These findings provide additional evidence that anatomic imaging to assess early response to therapy among patients with RMS does not predict outcome and has questionable use in tailoring subsequent therapy.

AB - Background The prognostic significance of response to induction therapy for rhabdomyosarcoma (RMS) by anatomic imaging [computerised tomographic (CT) or magnetic resonance imaging (MRI) scan] is controversial. We previously reported no relationship between early response and failure-free survival (FFS) on Intergroup Rhabdomyosarcoma Study (IRS)-IV. We repeated the same analysis using a more recent clinical trial as an independent cohort of patients with non-metastatic, initially unresected RMS. Methods A total of 338 patients enrolled in Children's Oncology Group (COG) study D9803 met the inclusion criteria for this analysis: (1) non-metastatic, initially unresected (Group III); (2) embryonal (ERMS) or alveolar (ARMS) histology; (3) documented protocol week 12 response to induction chemotherapy (excluding progressive disease) based on anatomic imaging (CT/MRI) and (4) documented protocol therapy beyond week 12. Response at week 12 was determined by the treating institution as complete response (CR), partial response (PR) or no response (NR). FFS was estimated using the Kaplan-Meier method and comparisons between patient subsets were made using the log-rank test. Results Overall objective response rate (CR + PR) at week 12 of therapy was 85% and was similar between ERMS and ARMS. FFS was similar among all patients with CR, PR or NR (p = 0.49). Restricting the analysis to either ERMS or ARMS, there was no difference in FFS by response within either histology subset (p = 0.89 and p = 0.08, respectively). Conclusions These findings provide additional evidence that anatomic imaging to assess early response to therapy among patients with RMS does not predict outcome and has questionable use in tailoring subsequent therapy.

KW - Paediatric cancer

KW - Rhabdomyosarcoma

KW - Sarcoma

KW - Survival outcomes

UR - http://www.scopus.com/inward/record.url?scp=84894030552&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894030552&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2013.11.031

DO - 10.1016/j.ejca.2013.11.031

M3 - Article

C2 - 24361229

AN - SCOPUS:84894030552

VL - 50

SP - 816

EP - 823

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 4

ER -